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T-cellsThe Pax5 and its isoforms inﬂuence proliferation of B- and T-cells, during development and oncogenesis but
molecular mechanism and host–tumor relationship is not clear. This report describes status of Pax5 isoforms
and co-regulation of molecular markers of ascite cells causing Dalton's lymphoma in murine. Higher
expressions of Pax5, CD19, CD3, Ras and Raf were observed in DLA cells. The levels of transcripts as well as p53
protein were also higher in DLA cells. The transcript of p53 from DLA cells was a variant of p53 having deletion
of 50 bp as compared to control. On annotation, it reﬂects transformation related protein p53 pseudogene
mRNA. Lower level of superoxide dismutase (SOD) indicates oxidative stress and higher level of LDH5 in DLA
cells reﬂects hypoxia in cancerous condition. The expression of Pax5d/e isoforms in DLA cells suggests
presence of resting B-cells. Thus, isoforms of Pax5 and co-regulation of T- and B-cells associated genes
inﬂuence phenotypic traits of ascetic cells causing Dalton's lymphoma.tor; CLL, Chronic lymphocytic
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The Pax5, a B-cell Speciﬁc Activator Protein (BSAP), is expressed
from the pro-B to mature lympho-plasmocytoid B-cells but remains
silence in plasma cells [1–5]. It inﬂuences cell proliferation, migration,
adhesion and signaling during development and oncogenesis [6]. It
regulates CD19 [7] and proliferation of B-cell but blocks T-cell
development [8,9]. Depending upon stages of B-cell development,
four characteristic isoforms of Pax-5, Pax-5a (full length Pax-5 or BSAP),
Pax-5b, Pax-5d and Pax-5e [10,11] have been observed in murine. The
literature suggests that the stimulation of the T-cell Receptor complex
[12] activates a cascade of biochemical events that triggers proliferation
and differentiation of T-cells. The zeta chain associated protein tyrosine
kinase, Zap70, [13] has been considered crucial for signaling by the TCR
[14–16] in T- and natural killer (NK)-derived cells, and B-chronic
lymphocytic leukemia, B-CLL [17–19], and CD19 positive splenic cells[20]. The expression of Zap-70 in B-CLL reﬂects that Zap-70 involves in
BCR and TCR mediated pathway for the development of non-Hodgkin
lymphoma. In normal B-cells, Pax5 regulates expression of CD19, but in
B-CLL the expression of CD19 is regulated by Zap-70. The literature also
suggests that CD19 regulates Zap-70 [21,22]. Pax5 also down regulates
p53 [23] that results into transformation of normal cells in to malignant
cells. Some enzymes like superoxide dismutase, SOD (E.C. 1.15.1.1) and
Lactate Dehydrogenase, LDH (E.C. 1.1.1.27) serve potential molecular
markers for assessing the progression of the proliferating malignant
cells [24], metabolic adaptation [25,26], pathological conditions [27,28],
and therapeutic monitoring [29]. In order to understand mechanism of
transformation, and proliferation of T- and/or B-cells, status of Pax5, and
associated molecular markers have been investigated using trans-
formed T-cells, capable of inducing Dalton's lymphoma (DL) in murine.
The development of DL has also been shown to be associated with
a concomitant inhibition of humoral, and cell mediated responses
[30,31]. It is presumed that cell-mediated response in DL seems
dominated by B-cells, which follow Ras-Raf mediated pathway to
establish high cell proliferation rate in comparison to other pathways.
The molecules involved in signal transduction may thus be post-
transcriptionally inﬂuenced. They may also reversibly react in vivo
against suppressive or activating factors.
2. Materials and methods
2.1. Animals and materials
The adult mice (15–20 weeks old) of AKR strain were used for all the
experiments because of their short life span and high susceptibility for
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feed and drinking water at 25±2 °C in animal house facility of the
department as per guidelines of the Institutional Animal Ethical
Committee. Dalton's lymphoma (DL) was induced by serial transplanta-
tion of live DLA cells as described earlier [32]. All chemicals used in the
experiment were of molecular biology and analytical grade. Primary
antibodies, anti-mousePax5 (Kindgift fromProf. S. Nutt's lab.), anti-rabbit
Ras (ab16909), anti-rabbit Raf (ab65050), anti-rabbit CD3 (ab5690),
anti-rabbit CD19 (ab63534), and anti-rabbit p53 (sc-6243) were
purchased from Santacruz Biotech, and Abcam. Anti-mouse Beta-actin
HRP-conjugated antibody (A3854)was purchased from Sigma. The TRITC
conjugated rabbit anti-mouse, FITC-conjugated goat anti-rabbit and HRP
conjugated secondary antibodies were purchased from Merk, and DAPI
(Molecular probe). FACS analysis was done according to suggested
protocol of kit (for CD4, CD8 and CD19) from BD Bioscience.
2.2. Phenotypic and molecular characterization of Dalton's lymphoma
ascite (DLA) cell
Mice were anesthetized with chloroform and ascite ﬂuid was
taken from the peritoneal cavity for Immunocytochemical and
phenotypic analysis. Ascite ﬂuids were centrifuged at 3000 rpm for
6 min to pellet cells. Cells were re-suspended in 1X Phosphate
Buffered Saline (PBS) and mixed with 2X trypan blue (Sigma) for
counting of viable cells using hemo-cytometer. Ascites cells from
control and lymphoma bearing mice were smeared on poly-L-Lysine
coated slides, ﬁxed by air-drying for 5 min. Slides were processed for
immuno-cytochemical staining and ﬂuorescence microscopy using
standard protocol of 3rd Gen IHC Detection kit (Invitrogen). Slides
were washed with phosphate buffer saline and probed with TRITC
rabbit anti-mouse and FITC goat anti-rabbit conjugated IgG secondary
antibodies and counter stained with DAPI to visualize the entire
population of cells. These cells were washed and suspended in 1X PBS
solution containing 0.1% FBS for phenotypic analysis. About 1×106
cells per tube were stained with the CD19-FITC, CD8-PE, and CD4-
Prey5 labeled antibody for 1 h at 4 °C. Finally, cells were washed and
re-suspended in 1X PBS containing 0.1% FBS, then analyzed on BD
FACS Caliber system.
2.3. Analysis of T- and B-cells associated molecular markers by RT-PCR
and Western blotting
Total RNAwas extracted from ascite cells from control and DLmice
using TRIzol (Invitrogen), and checked for the quality. Onemicrogram
of total RNA was reverse transcribed in 20 μl reaction mixture using
Oligo-dT primer according to suggested protocol for ﬁrst strand cDNA
synthesis kit (Fermentas). The resulting cDNA was used as a template
for PCR. All reactions were done in triplicate. The expression level of
Pax5, Zap-70, CD3, CD19, Ras, Raf, p53, LDH, and SOD was normalized
to the household gene β-actin, and speciﬁc genes were ampliﬁed with
the gene speciﬁc sets of primers as mentioned in Table 1.Table 1
Forward and reverse primers used (5′–3′) to amplify genes of interest in RT-PCR experime
Gene Name Forward primer (5′–3′)
Pax5PF CAACAAACGCAAGAGGG
Pax5PDF CGGACCATCAGGACAGGA
CD19F AAACCCAATTAGCCACTCAAATTCT
CD3F AAGTCGAGGACAGTGGCTACTAC
Zap-70 F GCACATATGCACTGTCCCTGGTCT
RafF TCCAGGAGACCAAATTCCAG
RasF TGTGGATGAGTACGACC
P53F AGAGACCGCCGTACAGAAGA
SODF TGGGGACAATACACAAGGCTGT
LDHF CGGCTCAACCTGGT
β-Actin TGACGGGGTCACCCACACTGTGCCCATCTAThe lysate of DLA cells was prepared in Tris-Cl buffer pH 7.4
containing 0.15 M NaCl, 0.2 mM PMSF and 5 mM EDTA. The protein
content of the sample was determined according to Lowry method
[33]. Twenty ﬁve micrograms of cell lysate was subjected to 10%
denaturing poly-acrylamide gel and blotted on to PVDF membrane
according to standard methods [34]. The blots were probed with
primary antibodies (1:5000 dilutions), anti-Pax5, anti-CD19, anti-
CD3, anti-Raf, anti-Ras, anti-p53, and respective secondary antibodies
(1:10000 dilutions). The ß-actin (A 3854, Sigma–Aldrich, Inc., USA)
was used as reference constitutive protein.
2.4. Assay of SOD and LDH
Native polyacrylamide gel (8%) electrophoresis was performed to
analyze active fraction of LDH and SOD. Electrophoresis was carried
out at 4 °C for three hours, applying a current of 100 mV. The gels
were stained for speciﬁc enzymes. The staining solution for LDH
comprised 0.1 M Tris-Cl buffer (pH 8.4), 1 mg ml−1 Nicotinamide
adinine dinucleotide (NAD+), 0.5 mg ml−1 Nitro blue tetrazolium
(NBT), 0.1 mg ml−1 Phenozine metho sulfate (PMS) and 0.05 M
lithium lactate. The staining mixture for SOD consists of phosphate
buffer 0.1 M (pH 7.4), 2.34 mM NBT, 28 μM riboﬂavin and 28 mM
NNN′N′ Tetramethlethylenediamine (TEMED) [35].
2.5. Characterization of apoptotic DLA cells by TUNEL assay
To analyze the presence of apoptotic bodies in ascite cells, TUNEL
assay was performed using Apo-Brdu-IHC™ In Situ DNA Fragmenta-
tion Assay Kit (Bio-Vision). After rinsing the slide it was counter-
stained with Methyl green and mounted with the help of mounting
media to observe under microscope.
2.6. Statistical analysis
The Integrative Density Value (IDV) of bands showing expressed
part of transcript was estimated using Alpha Ease FC (Alpha
Innotech,) software. Student's t-test was applied to determine the
difference between the means of control versus DL sample. The
histograms show values of means of relative density value of three
(N=3) separate experiments. The relative densities were taken
against the expressed part of β-actin respectively.
3. Results
3.1. Status of Pax5 isoforms in DLA cells
The line diagram (Fig. 1A) represents pair of primers (Table 1) to
analyze status of Pax5 and its isoforms. Three major PCR products
(Fig. 1B) with primer set “PDF/PR” indicate presence of Pax5a
(833 bp), Pax5b (430 bp), and Pax5d/e (210 bp) in control and DLA
cells. A product of 270 bp with primer set “PF/PR” suggests allnts.
Reverse primer (5′–3′)
Pax5PR GGGCTCGTCAAGTTGG
Pax5OctR CGGTGCTCACCGATGAC
CD19R CCAGGATGTACTCAGACCTCAGTTC
CD3R ATCAGCAAGCCCAGAGTGATACA
Zap-70R GGTCGCTGTAGGACTCTCGTACA
RafR GTGCAAGCATTGATGTCCTC
RasR ACGAATCCCGTAACTC
P53R GCATGGGCATCCTTTAACTC
SODR TTTCCACCTTTGCCCAAGTCA
LDHR TAGGCACTGTCCACCAC
β-Actin CTAGAAGCATTTGCGGTGGACGATGGAGGG
AB
C
D
Fig. 1. It represents the expression of Pax5 and its isoforms in ascite cells. Panel A, shows schematic representation of Pax5 isoforms, Pax5a, Pax5b, Pax5d and Pax5e. “P” represents
paired domain; “O”, octapeptide domain; “H”, homeo domain, “T”, transactivation domain and “U”, unique sequences in transactivation domain. Arrowswith primer name, represent
the position of forward and reverse primers from different regions of Pax5 cDNA whose RT-PCR products are resolved and represented from control (C) and DL ascite cells in
subsequent lanes of Panel B. PCR product with primer set “PDF/PR” testiﬁes Pax5a (833 bp), Pax5b (430 bp), and Pax5d/e (210 bp). Single product of 270 bp with primer set “PF/PR”
also conﬁrms all Pax5 isoforms while product of 363 bp with primer set “PDF/OCTR” preﬁgures Pax5b/e isoforms. Panel C, represents the western blot analysis of Pax5 and their
isoforms in ascite cells. The presence of Pax5a and Pax5d/e was observed in DLA cells as compared to only Pax5a in control. Panel D, shows expression of Pax5 in ascite cells through
immune-cytochemical analysis. Sub panels “a–c” represent expression of Pax5, with DAPI and merge images in control while “panels d–f” represent expression of Pax5, with DAPI
and merge images in DLA cells through confocal analysis.
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preﬁgures Pax5b/e isoforms. The western blot analysis (Fig. 1C)
foreshadows Pax5a in control, and an additional Pax5d/e in DLA cells.The immune-cytochemical analysis (Fig. 1D) testiﬁes expression of
Pax5 from control (panels “a–c”) and DLA cells (panels “d–f”) through
confocal analysis.
BA
Fig. 2. Panel A, shows analysis of transcripts by RT-PCR for genes from control and DLA cells. The histogram shows the higher expression of CD19 (124 bp), CD3 (163 bp) Zap-70
(1.5 kb), Raf (609 bp), and Ras (354 bp) in DLA cells. The expression level of unique band of p53 was lower in DLA cells. This novel band of p53 (200 bp) in DLA cells was smaller as
compared to control. Panel B, shows chromatogram of variant p53 sequence of DL ascite cells that has been submitted to NCBI. Sequence ID is GU808447 version GU808447.1. The
experiments were performed in triplicate (Pb0.05) ** shows signiﬁcance at the 0.05 and *** signiﬁcance at 0.001.
Fig. 3. It represents levels of protein markers like CD19 (61 kDa), CD3 (23 kDa), Raf (55 kDa), Ras (23 kDa) and p53 (53 kDa) in DLA cells throughWestern blot analysis as compared
to control. The experiments were performed in triplicate (Pb0.05) ** shows signiﬁcance at the 0.05 and *** signiﬁcance at 0.001.
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Fig. 4. It shows confocal microscope image of ascite cells, after immunostaining with anti-CD-19, and anti-CD3 followed by FITC-conjugated secondary antibody and counter stained
with DAPI from control (B–C) and DLA cells (E–F). The population of CD19 positive cells was higher in DLA cells as compared to control ascite cells. A one-parameter histogram of cell
count by ﬂow cytometer from control, and DLA shows CD19 positive cells (D). The histogram shows relatively high population of CD19 positive cells in DLA, and CD8 positive cells as
compared to control (D).
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oxidative stress
The presence of CD3, CD19, Zap70, Raf, Ras, and p53 was detected
by RT-PCR (Fig. 2A). It indicated that DLA cells consist of both T- and
B-cells. A unique transcript variant (Fig. 2B#) of p53 was also
observed in the DLA cells which has been sequenced, annotated, and
submitted to Genbank (GU808447 version GU808447.1). Levels oftranscripts (Fig. 2) as well as proteins (Fig. 3) of CD3, CD19, Raf, Ras,
and p53 in DLA cells were higher. The level of transcript of SOD and
active fraction of enzyme was lower but level of transcript of LDH and
active fraction (LDH5) was higher (Fig. 6). The β-actin transcript was
stable and taken as a positive control for the experiment.
The presence of T- and B-cells in DLA population was also
conﬁrmed by immunostaining and FACS analysis (Fig. 4). The confocal
imaging data of control ascite cells (Fig. 4B and C respectively) shows
Fig. 5. It shows confocal microscopy analysis of Ras, Raf and p53 positive cells in control
and DLA. The FITC signal (Green ﬂuorescence) localizes the Raf, Ras and p53 positive
cells and DAPI stained nuclei from control (A, C and E) and DLA (B, D and F). Raf (A), Ras
(C) and p53 (E) in control was localized in the cytoplasm at the external periphery of
the nucleus. In DLA cells immunostaining for Raf (B), Ras (D), and p53 (F) appeared
markedly stronger in the cytoplasm and slightly intense in the nucleus. Panels G, and H
show TUNEL assay from control and DLA cells that showmore positive cells in DLA cells.
Fig. 6. It shows levels of transcripts as well as active fractions of enzymes (SOD and
LDH) involved in stress responses. Panel A, shows lower expression of SOD (242 bp),
and higher expression of LDH (524 bp) in DLA cells as compared to control. Panel B,
testiﬁes lower activity of SOD, and higher activity of LDH. The experiments were
performed in triplicate (Pb0.05) *** shows signiﬁcance at 0.001.
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ﬂuorescence), but CD19 was located both at membrane and inside
the nucleus (blue ﬂuorescence) in DLA cells. Some light blue granular
reaction (Fig. 4E) was also evident while cap like feature of CD3
positive cells represented activated CD3 (Fig. 4F). More CD19 positive
cells were present in DLA cells (Fig. 4D) as compared to control ascite
cell population (Fig. 4A). The relative density of CD4 positive cells was
very low in DLA cells as compared to CD19 and CD8 positive cells
(Fig. 4D). The DLA cells show higher concentration of CD19 and CD8
positive cells in comparison to control (Fig. 4D).
The presence of Raf, Ras and p53 was also conﬁrmed by the
immunostaining analysis (Fig. 5). Presence of Raf was represented by
a brilliant, homogeneous green ﬂuorescence in the cytoplasm of DLA
cells (Fig. 5B), while in control ascite cells, ﬂuorescence was observed
at cytoplasmic membranous structure (Fig. 5A). Simultaneously, Ras
expression occurs at cytoplasm in both control (Fig. 5C) and DLA cells
(Fig. 5D). The p53 was located in cytoplasm (green ﬂuorescence), in
control ascite cells (Fig. 5E), although in DLA cells p53 located both in
cytoplasm and inside the nucleus (blue ﬂuorescence) with some light
blue granular reaction to a higher extent (Fig. 5F). The lower
expression of p53 and higher expression of Pax5 gives an idea about
the slow process of cell death and higher rate of proliferation
phenomenon that plays an important role in development of
lymphoma. In this regard, TUNEL analysis was performed in control
and DL ascite cells (Fig. 5), it shows high number of apoptotic cells in
DLA cells (Fig. 5H) in comparison to control ascite cells (Fig. 5G). This
result gives an idea about Pax5 modulated p53 dependent apoptosis
in lymphoma development, which was also supported by the lower
expression of p53 through both western blot analysis and RT-PCR
results.4. Discussion
The DLA cells were presumed to contain modiﬁed T-cells but it was
interesting to observe Pax5 isoforms, and Pax5 positive B-cells/or B-cell
lineages (Fig. 1A-D). Levels of transcripts (Fig. 1B) and proteins (Fig. 1C)
testify almost all Pax5 isoforms and Pax5 positive cells (Fig. 1D). The
data indicates B-cells proliferation because inﬂuence of alternatively
spliced forms of Pax5 during B-cell development has also been reported
[11]. Similarly, modulation of isoforms of Pax5 has been reported in
mice having lymphoid and myeloid abnormalities [36–39]. Expression
of Pax5d/e (Fig. 1C) in DLA cells suggests presence of more B-cells in
resting state which is also supported by Pax5-positivemore DLA cells. It
may be presumed that the activity of B-cells was modulated by
activation of T-õcell mediated response. The level of CD19was observed
to be higher in comparison to control (Figs. 2 and 3), which was likely
due to activation of B-cells but presence of Pax5d/e in DLA cells also
suggested thepresence of inactive B-lymphocyte. The higher expression
of Zap-70 and CD3 in the DLA cells (Fig. 2) indicates inﬂuence on TCR
complex in DLA cells. The B-cell receptor (BCR) complex for the B-cell
maturation requires the activation of numerous genes by Ras-derived
signals. The relatively higher expression of Ras and Raf transcripts in
DLA cells (Figs. 2 and 3) revealed that the growth of Dalton's lymphoma
either inﬂuences Ras-Raf mediated pathway or it is inﬂuenced by them.
The absence of wild-type p53 in DLA cells indicates the tumor
progression. However, appearance of a novel transcript shorter than
the wild-type p53 is highly interesting (Fig. 2B#). It reﬂects transfor-
mation related protein p53 pseudogene mRNA after annotation. The
co-regulation of CD3, Zap70, CD19, Ras, and Raf from DLA suggests TCR
associated regulation of cell proliferation. Similarly, regulation of CD19
by Zap70 [40] has also been described in Chronic Lymphocytic leukemia
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control also suggests that initial process is committed to Ras/Raf
dependent cell proliferation pathways [41,42]. Higher levels of Pax5,
and CD19 in DLA cells also provide an insight that conversion of
cancerous T-cells in to B-cell lineages is associated with CD19
expression. It is also likely thatduring ascetic growthmicroenvironment
develops that stimulate growth of B-cell under inﬂuence of Pax5. It is
supported by phenotypic characterization (Fig. 4) which describes that
aberrant T-cells population also expressed CD19. Similarly, expression
of CD19 in T-cell lymphomahas also been observed previously [43]. The
lower activity of SOD in DLA cells as compared to control suggests and
supports the variability of this enzyme system in lymphoma cells. The
higher level of LDH5 shows the induced hypoxic condition of DLA cells
(Fig. 6A and B) and indicates aggressiveness. Reactive oxygen
metabolites have also been implicated in the initiation and promotion
of cancer [44] and cancer cells are nearly always low in SOD [45,46].
5. Conclusion
Isoforms of Pax5 and co-regulation of T-and B-cells associated genes
inﬂuence phenotypic traits of ascetic cells causing Dalton's lymphoma.
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